|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NPEPPS |
Gene summary for NPEPPS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NPEPPS | Gene ID | 9520 |
| Gene name | aminopeptidase puromycin sensitive | |
| Gene Alias | AAP-S | |
| Cytomap | 17q21.32 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | B7Z899 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9520 | NPEPPS | CA_HPV_1 | Human | Cervix | CC | 1.84e-02 | -1.21e-01 | 0.0264 |
| 9520 | NPEPPS | CCI_1 | Human | Cervix | CC | 7.01e-13 | 1.89e+00 | 0.528 |
| 9520 | NPEPPS | CCI_2 | Human | Cervix | CC | 4.26e-11 | 1.09e+00 | 0.5249 |
| 9520 | NPEPPS | CCI_3 | Human | Cervix | CC | 3.86e-09 | 9.56e-01 | 0.516 |
| 9520 | NPEPPS | sample3 | Human | Cervix | CC | 2.63e-05 | 2.33e-01 | 0.1387 |
| 9520 | NPEPPS | L1 | Human | Cervix | CC | 1.50e-04 | 3.31e-01 | 0.0802 |
| 9520 | NPEPPS | T3 | Human | Cervix | CC | 9.94e-05 | 2.41e-01 | 0.1389 |
| 9520 | NPEPPS | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.13e-19 | -6.76e-01 | 0.0155 |
| 9520 | NPEPPS | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.33e-02 | -3.85e-01 | -0.1808 |
| 9520 | NPEPPS | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.47e-07 | -5.41e-01 | -0.1207 |
| 9520 | NPEPPS | HTA11_696_2000001011 | Human | Colorectum | AD | 6.47e-03 | -3.21e-01 | -0.1464 |
| 9520 | NPEPPS | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.28e-02 | -5.39e-01 | -0.0179 |
| 9520 | NPEPPS | HTA11_866_3004761011 | Human | Colorectum | AD | 1.76e-07 | -5.40e-01 | 0.096 |
| 9520 | NPEPPS | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.37e-02 | -5.07e-01 | 0.0338 |
| 9520 | NPEPPS | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.73e-10 | -4.27e-01 | 0.0674 |
| 9520 | NPEPPS | HTA11_6818_2000001021 | Human | Colorectum | AD | 5.45e-03 | -5.20e-01 | 0.0588 |
| 9520 | NPEPPS | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.91e-06 | -4.08e-01 | 0.294 |
| 9520 | NPEPPS | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.77e-02 | -5.00e-01 | 0.2585 |
| 9520 | NPEPPS | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.95e-12 | -4.11e-01 | 0.3005 |
| 9520 | NPEPPS | A001-C-207 | Human | Colorectum | FAP | 7.77e-04 | -2.18e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
| GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
| GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
| GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
| GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
| GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
| GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
| GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
| GO:00331579 | Cervix | CC | regulation of intracellular protein transport | 52/2311 | 229/18723 | 8.16e-06 | 1.88e-04 | 52 |
| GO:00705859 | Cervix | CC | protein localization to mitochondrion | 33/2311 | 125/18723 | 1.46e-05 | 2.90e-04 | 33 |
| GO:00323889 | Cervix | CC | positive regulation of intracellular transport | 46/2311 | 202/18723 | 2.45e-05 | 4.24e-04 | 46 |
| GO:00726559 | Cervix | CC | establishment of protein localization to mitochondrion | 31/2311 | 120/18723 | 4.13e-05 | 6.36e-04 | 31 |
| GO:000166610 | Cervix | CC | response to hypoxia | 61/2311 | 307/18723 | 1.04e-04 | 1.34e-03 | 61 |
| GO:007048210 | Cervix | CC | response to oxygen levels | 67/2311 | 347/18723 | 1.21e-04 | 1.51e-03 | 67 |
| GO:003629310 | Cervix | CC | response to decreased oxygen levels | 62/2311 | 322/18723 | 2.29e-04 | 2.57e-03 | 62 |
| GO:00066269 | Cervix | CC | protein targeting to mitochondrion | 25/2311 | 100/18723 | 3.80e-04 | 3.89e-03 | 25 |
| GO:00714539 | Cervix | CC | cellular response to oxygen levels | 38/2311 | 177/18723 | 4.23e-04 | 4.27e-03 | 38 |
| GO:00362949 | Cervix | CC | cellular response to decreased oxygen levels | 35/2311 | 161/18723 | 5.49e-04 | 5.29e-03 | 35 |
| GO:00714566 | Cervix | CC | cellular response to hypoxia | 33/2311 | 151/18723 | 7.06e-04 | 6.41e-03 | 33 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NPEPPS | SNV | Missense_Mutation | c.1013C>G | p.Ser338Cys | p.S338C | P55786 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| NPEPPS | SNV | Missense_Mutation | c.2219N>T | p.Ser740Phe | p.S740F | P55786 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NPEPPS | SNV | Missense_Mutation | c.2227C>G | p.Leu743Val | p.L743V | P55786 | protein_coding | deleterious(0) | possibly_damaging(0.629) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| NPEPPS | deletion | Frame_Shift_Del | novel | c.1864delC | p.Leu622SerfsTer13 | p.L622Sfs*13 | P55786 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| NPEPPS | SNV | Missense_Mutation | rs748154171 | c.2432N>T | p.Ser811Leu | p.S811L | P55786 | protein_coding | tolerated(0.19) | benign(0.028) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| NPEPPS | SNV | Missense_Mutation | c.769N>A | p.Glu257Lys | p.E257K | P55786 | protein_coding | deleterious(0.03) | possibly_damaging(0.457) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| NPEPPS | SNV | Missense_Mutation | c.916N>C | p.Asp306His | p.D306H | P55786 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| NPEPPS | SNV | Missense_Mutation | novel | c.1705N>T | p.Val569Phe | p.V569F | P55786 | protein_coding | tolerated(0.14) | benign(0.015) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NPEPPS | SNV | Missense_Mutation | rs746589578 | c.153C>G | p.Phe51Leu | p.F51L | P55786 | protein_coding | deleterious(0.01) | benign(0.424) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NPEPPS | SNV | Missense_Mutation | c.95C>T | p.Ser32Phe | p.S32F | P55786 | protein_coding | deleterious_low_confidence(0.04) | benign(0) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9520 | NPEPPS | PROTEASE, ENZYME, DRUGGABLE GENOME | CHR-2797 | TOSEDOSTAT | ||
| 9520 | NPEPPS | PROTEASE, ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL2103847 | TOSEDOSTAT | |
| 9520 | NPEPPS | PROTEASE, ENZYME, DRUGGABLE GENOME | inhibitor | 252166871 | ANTAQ |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |